Login to Your Account

Shotgun Partnering Approach for Vertex in All-Oral HCV Race

By Catherine Shaffer
Staff Writer

Friday, November 2, 2012

Moving aggressively to gain ground in the race for an all-oral hepatitis C virus (HCV) regimen, Vertex Pharmaceuticals Inc., of Cambridge, Mass., has put forward its nucleotide analogue HCV polymerase inhibitor, VX-135, in two collaborative, proof-of-concept Phase II trials with two different pharma partners.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription